Drugs / QX1206
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06694935 | Jan → Jul 2025 overdue | NAFLD1, type 2 diabetes mellitus | 1Globe Health Institute LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QX1206 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06694935 ↗ |
| Route | Oral | “administered orally before bedtime” NCT06694935 ↗ |